[go: up one dir, main page]

MX2016016363A - Compuestos que comprenden un sistema de 1,1',2,5'-tetrahidroespiro [indol-3,2'-pirrol]-2,5'-diona como inhibidores de la interaccion de proteina-proteina p53-mdm2. - Google Patents

Compuestos que comprenden un sistema de 1,1',2,5'-tetrahidroespiro [indol-3,2'-pirrol]-2,5'-diona como inhibidores de la interaccion de proteina-proteina p53-mdm2.

Info

Publication number
MX2016016363A
MX2016016363A MX2016016363A MX2016016363A MX2016016363A MX 2016016363 A MX2016016363 A MX 2016016363A MX 2016016363 A MX2016016363 A MX 2016016363A MX 2016016363 A MX2016016363 A MX 2016016363A MX 2016016363 A MX2016016363 A MX 2016016363A
Authority
MX
Mexico
Prior art keywords
protein
tetrahydrospiro
pyrrol
indole
inhibitors
Prior art date
Application number
MX2016016363A
Other languages
English (en)
Inventor
Feder Marcin
Kalinowska Iwona
Adriana Jaszczewska Joanna
Burchard Ewa
Lewandowski Wojciech
Bulkowska Urszula
Mazur Maria
Wos-Latosi Katarzyna
Original Assignee
Adamed Sp Zoo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adamed Sp Zoo filed Critical Adamed Sp Zoo
Publication of MX2016016363A publication Critical patent/MX2016016363A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Un compuesto de espirooxoindol representado por la fórmula seleccionada del grupo que consiste en la fórmula (IA) y (IB), en donde todos los símbolos son como se define en la descripción; el compuesto puede encontrar uso en un método de prevención y/o tratamiento de enfermedades seleccionadas del grupo que consiste en cáncer, enfermedades inmunes, condiciones inflamatorias, enfermedades de la piel alérgicas relacionadas con proliferación excesiva e infecciones virales. (ver Formulas).
MX2016016363A 2014-06-12 2015-06-11 Compuestos que comprenden un sistema de 1,1',2,5'-tetrahidroespiro [indol-3,2'-pirrol]-2,5'-diona como inhibidores de la interaccion de proteina-proteina p53-mdm2. MX2016016363A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL40854014 2014-06-12
PCT/IB2015/054425 WO2015189799A1 (en) 2014-06-12 2015-06-11 Compounds comprising 1,1',2,5'-tetrahydrospiro[indole-3,2'-pyrrole]-2,5'-dione system as inhibitors p53-mdm2 protein-protein interaction

Publications (1)

Publication Number Publication Date
MX2016016363A true MX2016016363A (es) 2017-04-06

Family

ID=54832985

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016016363A MX2016016363A (es) 2014-06-12 2015-06-11 Compuestos que comprenden un sistema de 1,1',2,5'-tetrahidroespiro [indol-3,2'-pirrol]-2,5'-diona como inhibidores de la interaccion de proteina-proteina p53-mdm2.

Country Status (13)

Country Link
US (1) US20170129903A1 (es)
EP (1) EP3154982B1 (es)
JP (1) JP2017517555A (es)
KR (1) KR20170012559A (es)
CN (1) CN106795168A (es)
AU (1) AU2015273106A1 (es)
BR (1) BR112016028888A2 (es)
CA (1) CA2947134A1 (es)
EA (1) EA030564B9 (es)
IL (1) IL248839A0 (es)
MX (1) MX2016016363A (es)
WO (1) WO2015189799A1 (es)
ZA (1) ZA201700110B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2858151T3 (es) 2016-05-20 2021-09-29 Hoffmann La Roche Conjugados de PROTAC-anticuerpo y procedimientos de uso
US11104684B2 (en) 2016-12-21 2021-08-31 Board Of Regents Of The University Of Nebraska Dimers of covalent NFKB inhibitors
BR112020013069A2 (pt) * 2017-12-29 2020-12-01 Gan & Lee Pharmaceuticals compostos capazes de serem usados como inibidor de tumor, método de preparação dos mesmos e aplicação dos mesmos
EP3511334A1 (en) * 2018-01-16 2019-07-17 Adamed sp. z o.o. 1,2,3',5'-tetrahydro-2'h-spiro[indole-3,1'-pyrrolo[3,4-c]pyrrole]-2,3'-dione compounds as therapeutic agents activating tp53
KR102039696B1 (ko) 2018-04-23 2019-11-04 충남대학교산학협력단 세포내 결핵균 제어를 위한 p53 발현 조절 가능한 조성물 (K279-1558) 또는 방법
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
CN114057756B (zh) * 2021-12-10 2022-12-09 山东第一医科大学(山东省医学科学院) 一种抗肿瘤活性的吡咯烷基螺氧化吲哚类化合物及其合成方法
WO2024078370A1 (zh) * 2022-10-13 2024-04-18 中国科学院上海药物研究所 具有取代苯基螺[吲哚啉-3,3'-吡咯烷]结构的小分子化合物
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof
CN119613416B (zh) * 2024-12-23 2025-11-04 聊城金歌合成材料有限公司 甲氧基螺吲哚吡咯烷酮化合物的合成方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030013656A1 (en) 2001-05-03 2003-01-16 Bing Wang Pyruvate derivatives
MY158766A (en) 2005-04-11 2016-11-15 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
US7994205B2 (en) 2006-03-31 2011-08-09 Takeda Pharmaceutical Company Limited Aryl-or heteroaryl-sulfonyl compounds as acid secretion inhibitors
RU2009117642A (ru) 2006-10-12 2010-11-20 Ксенон Фармасьютикалз Инк. (Ca) Применение спирооксиндоловых соединений в качестве терапевтических средств
US20110294842A9 (en) 2006-10-12 2011-12-01 Xenon Pharmaceuticals Inc. Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
US8217044B2 (en) * 2010-04-28 2012-07-10 Hoffmann-La Roche Inc. Spiroindolinone pyrrolidines
TWI494312B (zh) 2011-03-10 2015-08-01 Daiichi Sankyo Co Ltd 二螺吡咯啶衍生物
CN103717605B (zh) * 2011-05-11 2016-05-18 密执安州立大学董事会 螺-羟吲哚mdm2拮抗剂

Also Published As

Publication number Publication date
IL248839A0 (en) 2017-01-31
EP3154982B1 (en) 2018-05-02
EA030564B1 (ru) 2018-08-31
EA201692550A1 (ru) 2017-07-31
AU2015273106A1 (en) 2016-11-17
US20170129903A1 (en) 2017-05-11
CA2947134A1 (en) 2015-12-17
KR20170012559A (ko) 2017-02-02
CN106795168A (zh) 2017-05-31
JP2017517555A (ja) 2017-06-29
WO2015189799A1 (en) 2015-12-17
EP3154982A1 (en) 2017-04-19
ZA201700110B (en) 2018-04-25
BR112016028888A2 (pt) 2017-08-22
EA030564B9 (ru) 2019-02-28

Similar Documents

Publication Publication Date Title
MX2016016363A (es) Compuestos que comprenden un sistema de 1,1',2,5'-tetrahidroespiro [indol-3,2'-pirrol]-2,5'-diona como inhibidores de la interaccion de proteina-proteina p53-mdm2.
IL251285A0 (en) 3-substituted 5-amino-h6-triazolo[5,4-d]pyrimidine-7,2-dione compounds for the treatment and prevention of viral infection
SI3030563T1 (sl) Derivati pirolo (3,2-d) pirimidina za zdravljenje virusnih okužb in drugih bolezni
NZ712453A (en) Tricyclic heterocycles as bet protein inhibitors
GEP201706686B (en) Novel pyrrole compounds, preparation method thereof, and pharmaceutical compositions containing them
SG10201804306VA (en) THIENO[3,2-d]PYRIMIDINES DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS
SG10201908388UA (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2015003816A3 (en) Cystobactamides
EP3212658A4 (en) 2',2'-dihalo nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
MX2017000312A (es) Derivados de isoindolina para usarse en el tratamiento de una infeccion viral.
PH12015501588B1 (en) Compounds and methods for treating bacterial infections
AU2015352440B2 (en) Compounds
EP3134423A4 (en) 2' -disubstituted nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
MX2015009818A (es) Agonistas de receptores gamma activados por el proliferador de peroxisoma para el tratamiento de esclerosis multiple.
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
MY202127A (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
PH12015502564A1 (en) Pyridone derivatives for the treatment of viral infections and further diseases
IN2013MU03216A (es)
EA201500942A1 (ru) ПРОТИВОВИРУСНЫЙ ИНДОЛО[2,3-b]ХИНОКСАЛИН
EP2994156A4 (en) Compounds, compositions and methods for the treatment of diseases through inhibiting tgf- activity
WO2014176068A3 (en) Treatment and prevention of bacterial skin infections using oritavancin
SG10201903630UA (en) Iminosugars useful for the treatment of viral diseases
HK1231077A1 (en) Compounds comprising 1,1',2,5'-tetrahydrospiro[indole-3,2'-pyrrole]-2,5'-dione system as inhibitors p53-mdm2 protein-protein interaction
MX2015014657A (es) Nuevos agentes antibacterianos de fenicol.
UA66165U (ru) Применение витаминной композиции, которая содержит витамины С и К3, в качестве средства для лечения вирусных инфекций